Loading...
2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
BACKGROUND: Delafloxacin (DLX) is a fluoroquinolone, approved in the United States for treatment of ABSSSI. DLX has no preclinical signals for QT prolongation and has no QT prolongation in a validated challenge study. Risk of QT prolongation is a consideration in antibiotic selection for elderly hos...
Na minha lista:
| Udgivet i: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6810084/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1912 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|